VISEN Pharmaceuticals (VISEN PHARMA-B) disclosed that it bought back 14,900 ordinary shares on 15 June 2026 via on-market transactions on the Hong Kong Stock Exchange.

• Transaction details: The buy-backs were executed within a price range of HKD 19.50 to HKD 19.94 per share, at a volume-weighted average cost of HKD 19.64 per share. The aggregate consideration totalled HKD 0.29 million.

• Capital impact: Issued shares outstanding fell by 0.013 % to 113.79 million, while treasury shares increased from 125,800 to 140,700. Total issued shares remained unchanged at 113.93 million.

• Repurchase mandate utilisation: The current mandate, approved on 27 June 2025, authorises buy-backs of up to 11.39 million shares. Cumulative purchases under this authority now stand at 140,700 shares, representing 0.12 % of the shares outstanding when the mandate was granted.

• Post-repurchase restrictions: In line with Hong Kong listing rules, VISEN is subject to a moratorium on new share issues or treasury-share sales until 15 July 2026.

The board confirmed that the transaction complied with all relevant listing rules and regulatory requirements.